IDO1 and neoplasm: MDSCs are composed of multiple myeloid cells that are arrested at different stages of lineage development, which would be recruited to the TME by IDO1 overexpressing tumor cells, and then MDSCs inhibit T-cell function and reduce tumor response to immunotherapy in an IDO1-dependent manner (86–89).